Beijing Science Sun Pharmaceutical Co., Ltd. Class A

Beijing Science Sun Pharmaceutical Co., Ltd. Class A

SSZSE:300485
7.30
CNY
-0.09
(-1.22%)
-0.36EPS
4.17BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.34
1.64
1.44
1.29
1.57
2.98
2.48
2.26
2.19
1.54
0.97
0.85
0.83
0.74
Basic EPS, GAAP
0.45
0.56
0.5
0.54
0.59
0.59
0.31
0.32
0.84
0.43
0.21
-0.14
0.03
-0.35
Free Cash Flow per Basic Share
0.49
0.57
0.33
0.14
-0.07
-0.11
0.13
0.3
0.29
0.14
-0.06
0.07
-0.15
- -
Dividend per Share
0.08
0.14
0.13
0.09
0.13
0.12
0.12
0.06
0.07
0.17
0.08
0.02
- -
0.03
Book Value per Share
1.37
1.79
3.92
4.37
4.83
5.27
5.52
5.82
6.74
7
7.13
6.97
7
6.7
Tangible Book Value per Share
1.2
1.63
3.78
4.1
4.54
4.83
5.07
5.35
6.24
6.47
6.55
6.22
6.1
5.79
Basic Weighted Avg Shares
359
360
421
479
477
480
479
484
479
476
490
492
486
481
Sales/Revenue/Turnover
480
590
607
616
750
1,428
1,191
1,094
1,051
735
477
416
405
359
Operating Margin (%)
36.68
36.92
35.32
39.89
38.36
20.67
10.84
12.27
9.67
4.79
-8.61
5.95
-2.19
-6.68
Depreciation Expense
13
17
18
19
18
23
26
37
56
48
49
47
47
- -
Net Income, GAAP
161
203
209
258
282
283
149
155
402
205
103
-69
15
-167
Effective Tax Rate (%)
13.95
14.25
13.98
13.94
15.04
14.35
14.58
15.62
10
20.41
21.08
- -
36.69
- -
Profit Margin (%)
33.48
34.34
34.47
41.93
37.55
19.83
12.48
14.16
38.28
27.87
21.6
-16.53
3.6
-46.5
Working Capital
317
481
1,596
1,538
1,589
1,602
1,543
1,348
1,442
1,246
1,302
1,630
1,595
1,527
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
494
647
1,883
2,098
2,319
2,553
2,711
2,850
3,283
3,412
3,468
3,385
3,392
3,244
Return on Invested Capital (%)
36.46
34.57
16.38
12.88
12.73
11.54
5.72
5.47
12.92
6.07
2.8
- -
0.23
- -
Return on Capital (%)
37.69
33.12
16.22
12.93
12.71
11.58
5.69
5.71
13.35
6.18
3.18
- -
0.64
- -
Return on Common Equity (%)
37.82
35.63
16.57
12.99
12.76
11.63
5.69
5.65
13.3
6.19
3.02
-2.03
0.43
-5.03

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
20
14
29
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
482
482
482
Market Capitalization
5,207
4,581
4,166

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,751
1,595
1,611
Cash, Cash Equivalents & STI
1,621
1,473
1,496
Accounts Receivable, Net
39
37
35
Inventories
72
71
67
Total Current Liabilities
87
75
84
Payables & Accruals
- -
- -
- -
ST Debt
20
14
29
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.2%
3.72%
0.21%
Free Cash Flow
-95.05%
-144.83%
-310.07%
Net Income, GAAP
-23.75%
-45.44%
-121.16%
Sales/Revenue/Turnover
0.42%
-16.92%
-2.82%
Total Cash Common Dividend
-9.08%
-11.65%
-97.63%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
110
105
108
94
416
2025
93
104
- -
96
405
2026
90
90
82
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.4
0.18
0.01
0.06
-0.14
2025
0.08
0.02
- -
-0.08
0.03
2026
0.01
-0.31
0.03
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.02
2025
- -
- -
- -
- -
- -
2026
- -
0.03
- -
- -
- -

Company Description

CEO
Biao Ma
Full Time Employees
489
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.8, Xingsheng Street Beijing BE China 100176
IPO Date
Jun 16, 2015
Business
Beijing Science Sun Pharmaceutical Co., Ltd. (300485.SZ) engages in the research, development, production, and sale of biological and biochemical injections in China. The company offers core products covering cardiovascular and cerebrovascular diseases, immune diseases including anti-tumor applications, neurological diseases, and other therapeutic varieties; it also researches and produces raw materials, traditional Chinese medicine extracts, Chinese and Western medicine preparations, bio-organic fertilizers, and bio-feeds while providing consulting, venture capital, and equity investment services. Founded in 1999 and headquartered at No. 8 Xingsheng Street, Beijing Economic and Technological Development Zone, Beijing, China, the company operates primarily across domestic regions including East China, Northeast China, Central China, Northern China, Southwest China, South China, and Northwestern China. Subsidiaries include Beijing Luzhu Biotechnology Co., Ltd., in which it holds a 6.79% stake. Recent developments encompass approval for site relocation in July 2025, a subsidiary's transfer of a protein production project for 20 million yuan in June 2025, an agreement to acquire a 5.6664% stake in Suzhou Inhal Pharma Co., Ltd., and the release of its 2025 semi-annual report along with third-quarter performance disclosures.